{"id":"NCT03491462","sponsor":"ZevraDenmark","briefTitle":"Arimoclomol in Amyotropic Lateral Sclerosis","officialTitle":"A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-31","primaryCompletion":"2020-12-18","completion":"2020-12-18","firstPosted":"2018-04-09","resultsPosted":"2023-08-24","lastUpdate":"2023-08-24"},"enrollment":245,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Arimoclomol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arimoclomol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)","primaryOutcome":{"measure":"Combined Assessment of Function and Survival (CAFS)","timeFrame":"Over 76 Weeks","effectByArm":[{"arm":"Arimoclomol (up to 76 Weeks)","deltaMin":0.51,"sd":0.291},{"arm":"Placebo (up to 76 Weeks)","deltaMin":0.49,"sd":0.283}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6208"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":29,"countries":["United States","Belgium","Canada","France","Germany","Italy","Netherlands","Poland","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["38782015"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":160},"commonTop":["Headache","Fall","Constipation","Insomnia","Nausea"]}}